CD98 siRNA

CD98 siRNA is a **small interfering RNA (siRNA)** therapeutic designed to downregulate CD98 (also known as 4F2 heavy chain or SLC3A2) expression at the messenger RNA level. CD98 is a type II transmembrane glycoprotein that functions as both an amino acid transporter (when complexed with light chains) and a regulator of integrin signaling. The siRNA is typically delivered using nanoparticle-based systems, most commonly **polylactic acid (PLA) nanoparticles** complexed with **polyethylenimine (PEI)** to facilitate endosomal escape and cytosolic release. The therapeutic mechanism involves RNA interference-mediated knockdown of CD98 mRNA, leading to reduced protein expression. This approach has been investigated for multiple inflammatory conditions, including **inflammatory bowel disease (IBD)**, **colitis**, and **non-alcoholic fatty liver disease (NAFLD)**. Studies have demonstrated that CD98 siRNA delivered via nanoparticles can effectively reduce CD98 expression in epithelial cells and macrophages, subsequently decreasing pro-inflammatory cytokine production (TNF-α, IL-1β, IFN-γ, Cox-2, IL-6). The nanoparticle delivery system typically produces particles around **275-280 nm in diameter** and has been shown to preferentially target the liver, kidney, and spleen following intravenous administration, with significant uptake in hepatocytes and Kupffer cells. For gastrointestinal applications, oral administration of hydrogel-encapsulated siRNA/PEI-loaded nanoparticles has been used to target colonic epithelial cells and macrophages.

Other names

CD98 siRNA-loaded nanoparticlesCD-98 siRNA-loaded nanoparticlesCD 98 siRNA-loaded nanoparticlesCD98 siRNA/PEI-loaded nanoparticles